Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

Accelerated rTMS for Apathy in Parkinson's DiseaseRecruiting
NCT07399496NAUpdated Aug 27, 2026
Sponsor: Medical University of South Carolina
Parkinson Disease
United States
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)Completed
NCT03615326Phase 3Updated Aug 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma
United States, Australia, Brazil, Chile, China +15 more
Effects of Tai Chi Therapy Versus Qi-Gong in Stage-I Parkinson's Patients.Recruiting
NCT07662837NAUpdated Aug 26, 2026
Sponsor: Lahore University of Biological and Applied Sciences
PARKINSON DISEASE (Disorder)
Pakistan
Physiological Brain Atlas DevelopmentRecruiting
NCT00575081N/AUpdated Aug 26, 2026
Sponsor: Vanderbilt University Medical Center
Parkinson's Disease · Obsessive Compulsive Disorder · Dystonia · Essential Tremor
United States
Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed ConditionsCompleted
NCT05128175Phase 1Updated Aug 26, 2026
Sponsor: Shanghai WD Pharmaceutical Co., Ltd.
Parkinson Disease
India
Lithium for Parkinson's: an Extension TrialEnrolling By Invitation
NCT06592014Phase 1, Phase 2Updated Aug 25, 2026
Sponsor: State University of New York at Buffalo
Parkinson Disease
United States
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's DiseaseRecruiting
NCT07428447N/AUpdated Aug 25, 2026
Sponsor: CND Life Sciences
Essential Tremor, Movement Disorders · Essential Tremor · Essential Tremor-plus
United States
The Effect of the Reaction Training in Parkinson's DiseaseCompleted
NCT06807385NAUpdated Aug 25, 2026
Sponsor: Gazi University
Parkinson' Disease
Turkey (Türkiye)
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting
NCT04165798N/AUpdated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Recruiting
NCT06780085Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Chile, Germany, Greece, Hungary +5 more
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological ConditionsRecruiting
NCT07786116NAUpdated Aug 25, 2026
Sponsor: University of Cambridge
PARKINSON DISEASE (Disorder) · Parkinson · Parkinson Disease · Parkinson s Disease
United Kingdom
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)Recruiting
NCT04165070Phase 1, Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
Characterization and Validation of the Short Physical Performance Battery in Individuals Diagnosed With Parkinson's DiseaseRecruiting
NCT07780461N/AUpdated Aug 25, 2026
Sponsor: University of Vigo
PARKINSON DISEASE (Disorder)
Spain
CnF-DBS for Levodopa-Resistant FOGNot Yet Recruiting
NCT07781696NAUpdated Aug 24, 2026
Sponsor: Iahn Cajigas
Freezing of Gait Symptoms in Parkinson Disease
United States
tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's DiseaseCompleted
NCT04606979NAUpdated Aug 24, 2026
Sponsor: Vrije Universiteit Brussel
Parkinson Disease · Parkinson · Healthy
Belgium
Correlation of STN-DBS Induced Visuospatial Changes and Freezing of GaitRecruiting
NCT06994728NAUpdated Aug 24, 2026
Sponsor: Medical University of South Carolina
Parkinson Disease · Gait Disorders, Neurologic · Visuospatial/Perceptual Abilities
United States
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.Not Yet Recruiting
NCT07764874NAUpdated Aug 24, 2026
Sponsor: InSightec
Parkinson Disease
South Korea
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesRecruiting
NCT07002034Phase 2Updated Aug 24, 2026
Sponsor: Reunion Neuroscience Inc
Adjustment Disorder
United States
A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson DiseaseRecruiting
NCT07705373NAUpdated Aug 24, 2026
Sponsor: Boston University Charles River Campus
Parkinson's Disease (PD)
United States
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson'sRecruiting
NCT04664634Phase 3Updated Aug 24, 2026
Sponsor: Northwestern University
Dysphagia · Parkinson Disease
United States
Study to Test Effects and Safety of RO7568282 in Early Parkinson's DiseaseNot Yet Recruiting
NCT07781644Phase 1, Phase 2Updated Aug 24, 2026
Sponsor: Hoffmann-La Roche
Parkinson's Disease
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)Recruiting
NCT06996652Phase 2Updated Aug 24, 2026
Sponsor: Yale University
REM Sleep Behavior Disorder
United States, Canada
GBPDC: Gut-Brain in PD Consortium Master ProtocolRecruiting
NCT07567794N/AUpdated Aug 21, 2026
Sponsor: Duke University
Parkinson Disease (PD) · PARKINSON DISEASE (Disorder) · Gut Microbiome · Gut Microbiota
United States
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).Terminated
NCT04949256Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Esophageal Squamous Cell Carcinoma
United States, Argentina, Canada, Chile, China +20 more
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.Recruiting
NCT06466525Phase 1Updated Aug 21, 2026
Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
Parkinson Disease
Australia

Previous page Next page